Patents by Inventor Shu-Hsien CHANG

Shu-Hsien CHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oral pH independent dosage formulation for treating neurodegenerative disorders
    Patent number: 10894023
    Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: January 19, 2021
    Assignee: CENTER LABORATORIES, INC.
    Inventors: Meng-Ju Lee, Shu-Hsien Chang, Chih-Chiang Yang, Yuan-Chih Le, Tse-Ching Lin, Ko-Chiang Chen, Lai-Cheng Chin, Tai-Yin Ke, Pei-Ying Liao
  • Method of treating hyperglycemia
    Patent number: 10639292
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Grant
    Filed: November 3, 2018
    Date of Patent: May 5, 2020
    Assignee: CENTER LABORATORIES, INC.
    Inventors: Jui-Pao Hsu, Guang-Tzuu Shane, Meng-Ju Lee, Yi-Ping Liao, Yu-Yin Yeh, Shu-Hsien Chang
  • ORAL pH INDEPENDENT DOSAGE FORMULATION FOR TREATING NEURODEGENERATIVE DISORDERS
    Publication number: 20190388340
    Abstract: Disclosed herein is an oral dosage formulation suitable for treating a neurodegenerative disorder. The oral dosage formulation contains both sustained-release and immediate-release drugs. The sustained-release drug in the oral dosage formulation is memantine, and the immediate-release drug in the oral dosage formulation is donepezil and/or memantine, and the formulation is characterized in having a pH-independent dissolution profile of memantine at a pH range from about 1.0 to about 7.0.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Applicants: Center Laboratories, Inc., Medical and Pharmaceutical Industry Technology and Development Center
    Inventors: Meng-Ju LEE, Shu-Hsien CHANG, Chih-Chiang YANG, Yuan-Chih LE, Tse-Ching LIN, Ko-Chiang CHEN, Lai-Cheng CHIN, Tai-Yin KE, Pei-Ying LIAO
  • METHOD OF TREATING HYPERGLYCEMIA
    Publication number: 20190321326
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. Such conditions and/or disorders related to hyperglycemia include, but are not limited to, type I, II diabetes mellitus, gestational diabetes, other forms diabetes, and disorders related thereto. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and an ?-glycosidase inhibitor in the treatment of conditions and/or disorders related to hyperglycemia.
    Type: Application
    Filed: November 3, 2018
    Publication date: October 24, 2019
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH, Shu-Hsien CHANG
  • METHOD OF TREATING HYPERGLYCEMIA
    Publication number: 20190321327
    Abstract: Disclosed herein are methods for treating conditions and/or disorders related to hyperglycemia. In particular, the present invention relates to methods of using (R)-(+)-verapamil or a pharmaceutically acceptable salt thereof and insulin or an insulin analogue in the treatment of mellitus and/or disorders related to diabetes mellitus.
    Type: Application
    Filed: March 25, 2019
    Publication date: October 24, 2019
    Applicant: Center Laboratories, Inc.
    Inventors: Jui-Pao HSU, Guang-Tzuu SHANE, Meng-Ju LEE, Yi-Ping LIAO, Yu-Yin YEH, Shu-Hsien CHANG